Hereditary Angioedema Therapeutics Market Expected to Reach USD 5.4 Billion by 2031 | Pharming Healthcare, Inc, Sanofi, Attune Pharmaceuticals, Inc.

The Global Hereditary Angioedema Therapeutics Market reached USD 2.9 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 5.4 billion by 2031. The global hereditary angioedema therapeutics market is expected to exhibit a CAGR of 8.6% during the forecast period (2024-2031).

The Hereditary Angioedema Therapeutics market report provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. With a commitment to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Leveraging a combination of qualitative and quantitative research methods, the company offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/hereditary-angioedema-therapeutics-market

The Hereditary Angioedema (HAE) Therapeutics Market focuses on treatments for HAE, a rare genetic disorder characterized by episodes of severe swelling in various parts of the body. Market growth is driven by advancements in targeted therapies, such as C1 inhibitor therapies, bradykinin receptor antagonists, and gene therapies. Increasing awareness, improved diagnostic techniques, and the rising demand for personalized treatment options are fueling market expansion, alongside a growing patient population and regulatory support for orphan drugs.

Forecast Growth Projected:

The Global Hereditary Angioedema Therapeutics Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Transform your pharma strategy with expert insights and competitive analysis: https://www.datamintelligence.com/competitive-intelligence/contact

List of the Key Players in the Hereditary Angioedema Therapeutics Market:

BioCryst Pharmaceuticals, Inc, CSL Behring LLC, Takeda Pharmaceutical Company, Pharming Healthcare, Inc, Sanofi, Attune Pharmaceuticals, Inc, Ionis Pharmaceuticals, KalVista Pharmaceuticals, Inc, Arrowhead Pharmaceuticals, and Advanced Technology & Industrial Co., Ltd, among others.

Industry Development:

In January 2025, Intellia Therapeutics, Inc. announced the dosing of the first patient in its global Phase 3 trial for NTLA-2002, a CRISPR-based therapy aimed at treating hereditary angioedema (HAE). NTLA-2002 is an innovative, in vivo, single-dose treatment being developed to address this potentially life-threatening condition. Intellia anticipates completing patient enrollment in the second half of 2025 and plans to submit a Biologics License Application (BLA) in 2026, with hopes to launch the therapy in the U.S. by 2027.

On November 18, 2024, BioCryst Pharmaceuticals, Inc. announced that Ireland's Health Services Executive (HSE) recommended ORLADEYO (berotralstat) for the routine prevention of recurrent HAE attacks in eligible patients aged 12 and older. This recommendation marks an important milestone, providing Irish patients with access to the first oral, once-daily treatment designed to reduce the frequency of recurrent HAE attacks.

Research Methodology

Our research methodology combines both qualitative and quantitative approaches to provide you with a thorough market analysis. We begin by gathering data from trusted industry reports and databases (secondary research), followed by primary research through surveys and interviews with key experts. We then apply advanced statistical tools to analyze the data, uncover trends, and assess market dynamics. Additionally, we use market segmentation and Porter's Five Forces analysis to evaluate competition. This approach ensures that the insights we provide are reliable, actionable, and tailored to support your decision-making process.

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/hereditary-angioedema-therapeutics-market

Segment Covered in the Hereditary Angioedema Therapeutics Market:

By Drug class: Kallikrein Inhibitor, C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Others.

By Treatment Type; On-demand, Prophylaxis.

By Route of Administration: Intravenous, Subcutaneous, Oral.

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, Market Access, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Regional Analysis for Hereditary Angioedema Therapeutics Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.

➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market

Speak to Our Senior Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/hereditary-angioedema-therapeutics-market

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of Hereditary Angioedema Therapeutics market?

➠ Who are the global key manufacturers of the Hereditary Angioedema Therapeutics Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the Hereditary Angioedema Therapeutics market opportunities and threats faced by the vendors in the global Hereditary Angioedema Therapeutics Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the Hereditary Angioedema Therapeutics market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.